Flying with nut and other food allergies: unravelling fact from fiction

There is a common perception that peanut/tree nut particles can be transmitted through aircraft ventilation systems and pose a significant risk to passengers with food allergies. In fact, food-induced allergic reactions are around 10-100 times less common during flights than ‘on the ground’, perhaps because of the multiple precautions food-allergic passengers take when flying. We […]

Air pollution is associated with persistent peanut allergy in the first 10 years

Background: The role of air pollution in eczema and food allergy development remains understudied. Objective: We aimed to assess whether exposure to air pollution is associated with eczema and food allergies in the first 10 years of life. Methods: HealthNuts recruited a population-based sample of 1-year-old infants who were followed up at ages 4, 6, […]

Peanut allergen characterization and allergenicity throughout development

Introduction: Peanut allergy (PA) in children is a major concern. There is a need for better biological material for both diagnosis and oral immunotherapy (OIT) treatments. The unique state of seeds at early reproductive stages may affect the allergenicity of storage proteins, and impact clinical diagnostic and OIT protocols. The objective of this study was […]

Epicutaneous immunotherapy for the treatment of peanut allergy

Peanut allergy treatment options remain limited, but novel approaches are being studied, including epicutaneous immunotherapy (EPIT). EPIT uses the cutaneous immune system to promote tolerance to food allergens. Viaskin™ Peanut, an approach to EPIT in late-stage clinical development uses an occlusive patch with a condensation chamber that enables natural epidermal water loss to solubilize dry […]

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study With Single Blind Sentinel Period to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IGNX001 in Peanut-Allergic Participants

The goal of this randomized, double-blind, placebo-controlled, single ascending dose clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IGNX001 in peanut-allergic adults and older Adolescents. https://clinicaltrials.gov/study/NCT06331728

Successful introduction of peanut in sensitized infants with reported reactions at home

Background and objective: Previous studies have shown efficacy of early introduction of peanut to prevent peanut allergy. It is currently unknown which diagnostic pathway is optimal after parental-reported reactions to peanut at home after early introduction. Methods: The PeanutNL cohort study included high-risk infants that were referred for early introduction of peanut. A subgroup of […]